Cargando…

Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy

Recent unprecedented advances in treatment for spinal muscular atrophy (SMA) enabled patients to access the first approved disease modifying therapy for the condition. There are however many uncertainties, regarding timing of treatment initiation, response to intervention, treatment effects and long...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kariyawasam, Didu S. T., D'Silva, Arlene, Lin, Cindy, Ryan, Monique M., Farrar, Michelle A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709682/ https://www.ncbi.nlm.nih.gov/pubmed/31481927 http://dx.doi.org/10.3389/fneur.2019.00898

Ejemplares similares

Integrating newborn screening for spinal muscular atrophy into health care systems: an Australian pilot programme
por: D'Silva, Arlene M, et al.
Publicado: (2021)

Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen
por: Kariyawasam, Didu, et al.
Publicado: (2021)

Identification of Novel CSF-Derived miRNAs in Treated Paediatric Onset Spinal Muscular Atrophy: An Exploratory Study
por: D’Silva, Arlene M., et al.
Publicado: (2023)

“We needed this”: perspectives of parents and healthcare professionals involved in a pilot newborn screening program for spinal muscular atrophy
por: Kariyawasam, Didu S.T., et al.
Publicado: (2021)

Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy
por: D'Silva, Arlene M., et al.
Publicado: (2022)

Gene therapy-based strategies for spinal muscular atrophy—an Asia-Pacific perspective
por: Farrar, Michelle A., et al.
Publicado: (2023)

Incidence of Duchenne muscular dystrophy in the modern era; an Australian study
por: Kariyawasam, Didu, et al.
Publicado: (2022)

Clinical Phenotyping and Biomarkers in Spinal and Bulbar Muscular Atrophy
por: Millere, Elina, et al.
Publicado: (2021)

Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives
por: Farrar, Michelle A, et al.
Publicado: (2018)

“Getting ready for the adult world”: how adults with spinal muscular atrophy perceive and experience healthcare, transition and well-being
por: Wan, Hamish W. Y., et al.
Publicado: (2019)

Spinal Muscular Atrophy: The Treatment Approved
por: Tabet, Rabih, et al.
Publicado: (2017)

Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment?
por: Savini, Giovanni, et al.
Publicado: (2021)

Role of circulating biomarkers in spinal muscular atrophy: insights from a new treatment era
por: Giorgia, Querin, et al.
Publicado: (2023)

Editorial: Spinal Muscular Atrophy: Evolutions and Revolutions of Modern Therapy
por: Finkel, Richard S., et al.
Publicado: (2020)

Expression of Human Endogenous Retrovirus-K in Spinal and Bulbar Muscular Atrophy
por: Rex, Cody, et al.
Publicado: (2019)

Circulating microRNAs as potential biomarkers and therapeutic targets in spinal muscular atrophy
por: Chen, Tai-Heng
Publicado: (2020)

Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy
por: Elsheikh, Bakri, et al.
Publicado: (2021)

Neurofilament as a potential biomarker for spinal muscular atrophy
por: Darras, Basil T., et al.
Publicado: (2019)

Correlation Between Maximal Tongue Pressure and Swallowing Function in Spinal and Bulbar Muscular Atrophy
por: Gwak, Dae-Won, et al.
Publicado: (2021)

Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy
por: Kotulska, Katarzyna, et al.
Publicado: (2021)

Serum Creatine, Not Neurofilament Light, Is Elevated in CHCHD10-Linked Spinal Muscular Atrophy
por: Järvilehto, Julius, et al.
Publicado: (2022)

Real-World Data on Access to Standards of Care for People With Spinal Muscular Atrophy in the UK
por: Muni-Lofra, Robert, et al.
Publicado: (2022)

Sociodemographic and clinical characteristics and access to health care in patients with spinal muscular atrophy in Argentina
por: Vazquez, Gabriel Adolfo, et al.
Publicado: (2023)

The Carrier Frequency of Two SMN1 Genes in Parents of Symptomatic Children with SMA and the Significance of SMN1 Exon 8 in Carriers
por: Davidson, Joanne E, et al.
Publicado: (2023)

Update on Biomarkers in Spinal Muscular Atrophy
por: Pino, Megan G, et al.
Publicado: (2021)

The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs
por: Hensel, Niko, et al.
Publicado: (2020)

Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen
por: Wurster, Claudia D., et al.
Publicado: (2019)

Spinal Muscular Atrophy and Communicating Hydrocephalus: A Novel or a Well-Established Rare Association?
por: Alkhars, Fatimah Z, et al.
Publicado: (2020)

Addressing the implementation gap in advanced therapeutics for spinal muscular atrophy in the era of newborn screening programs
por: Leon-Astudillo, Carmen, et al.
Publicado: (2022)

Lowered oxidative capacity in spinal muscular atrophy, Jokela type; comparison with mitochondrial muscle disease
por: Ratia, Nadja, et al.
Publicado: (2023)

Emerging therapies and challenges in spinal muscular atrophy
por: Farrar, Michelle A., et al.
Publicado: (2017)

Ethical Perspectives on Treatment Options with Spinal Muscular Atrophy Patients
por: Yeo, Crystal J. J., et al.
Publicado: (2022)

Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis
por: Darbà, Josep, et al.
Publicado: (2019)

Case report: A case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment
por: Nigro, Elisa, et al.
Publicado: (2023)

Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy
por: Farrar, Michelle A., et al.
Publicado: (2011)

Healthcare Utilization, Costs of Care, and Mortality Among Patients With Spinal Muscular Atrophy
por: Tan, Hiangkiat, et al.
Publicado: (2019)

Healthcare Utilization, Costs of Care, and Mortality Among Patients With Spinal Muscular Atrophy
por: Tan, Hiangkiat, et al.
Publicado: (2019)

Longitudinal characterization of biomarkers for spinal muscular atrophy
por: Bonati, Ulrike, et al.
Publicado: (2017)

Exploratory evaluation of an eye-tracking system in patients with advanced spinal muscular atrophy type I receiving nusinersen
por: Yae, Yukako, et al.
Publicado: (2022)

Cognitive impairment in Chinese adult patients with type III spinal muscular atrophy without disease-modifying treatment
por: Hu, Ying, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vqikdlu5i4k77ss876dpq4pml0